Zoetis Cuts 2026 Outlook as Companion Animal Demand Falters

What happened

Zoetis lowered its full-year 2026 guidance, citing weaker veterinary traffic, intensified price sensitivity, and rising competition in its core companion animal segment. The company is now using promotions to defend market share, signaling a more defensive posture than previously communicated. This move aligns with the bear case from the master report, which highlighted risks from Librela safety concerns and tightening pricing power. The guidance cut indicates the OA monoclonal antibody franchise is not recovering as hoped, and competitive encroachment is eroding Zoetis’s historical pricing umbrella. As a result, the margin of safety narrows, and the stock may face further multiple compression unless organic growth reaccelerates.

Implication

Investors should reassess the recovery timeline; without a clear OA mAb inflection or stabilization in companion animal trends, the stock could drift toward the bear-case value of $100. The promotion strategy suggests management is prioritizing volume over price, which could signal a more competitive landscape. Until evidence of a sustainable demand recovery emerges, the risk/reward remains unfavorable, and a better entry point near $110 would be more compelling. Maintain a wait stance; re-evaluate if organic growth reaccelerates above 8% or OA revenue stabilizes.

Thesis delta

The 2026 outlook cut and shift to promotions confirm that companion animal headwinds are deeper than initially forecast, raising the probability of the bear case. The wait-for-better-entry stance remains prudent, but the expected recovery timeline has elongated, and the stock may test lower support before stabilizing.